NYSE:ABBVBiotechs
Assessing AbbVie (ABBV) Valuation After Positive Phase 3 Epcoritamab Lymphoma Results
Phase 3 lymphoma data puts AbbVie (ABBV) oncology in focus
AbbVie (ABBV) is drawing fresh attention after reporting Phase 3 results for epcoritamab in relapsed or refractory diffuse large B cell lymphoma, with the bispecific antibody improving progression free survival versus chemoimmunotherapy.
See our latest analysis for AbbVie.
Against this backdrop, AbbVie’s 1 day share price return of 0.91% and 7 day return of 0.63% sit alongside a softer 30 day share price return of a 4.67% decline and...